Print Page  Close Window

SEC Filings

DEF 14A
ACETO CORP filed this Form DEF 14A on 10/20/2017
Entire Document
 << Previous Page | Next Page >>

 

 

PROPOSAL ONE

 

ELECTION OF DIRECTORS

 

THE NOMINEES

 

The Board is proposing a slate of directors that consists of seven incumbent directors. Mr. Hans C. Noetzli will not be standing for re-election.

 

The names of the nominees, their ages (as of October 10, 2017), their committee positions and the period during which they have been serving on our Board are set forth in the table below:

 

NAME   AGE   AUDIT & RISK
COMMITTEE
  COMPENSATION
COMMITTEE
  NOMINATING &
GOVERNANCE
COMMITTEE
  DIRECTOR
SINCE
Albert L. Eilender (1)   74               2000
William C. Kennally, III   61               2016
Vimal Kavuru   49               2017
William N. Britton   72   C       X   2006
Natasha Giordano   57       C       2011
Alan G. Levin   55   X       C   2013
Dr. Daniel B. Yarosh   63   X   X   X   2014

 

 

(1) Chairman of the Board

C – Chairperson

X – Committee member

 

One current compensation committee member, Hans C. Noetzli, is not standing for re-election. Mr. Kennally ceased serving on our compensation committee on September 27, 2017, when our Board determined that Mr. Kennally would succeed Salvatore Guccione as president and chief executive officer of Aceto, effective as of October 2, 2017. On September 27, 2017, Dr. Daniel B. Yarosh was named to the compensation committee to replace Mr. Kennally.

 

It is the intention of the persons named in the proxy card to vote all shares of common stock for which they have been granted a proxy for the election of the nominees, each to serve as a director for a term of office of one year and until his or her successor shall have been duly elected. All the nominees have consented to being named in this proxy statement and to serve as a director if elected.

 

At the time of the annual meeting, if any of the nominees named above is not available to serve as director (an event that the Board does not currently have any reason to anticipate), all proxies will be voted for any one or more other persons that the Board designates. The Board believes that it is in the best interests of the Company to elect the above-described nominees.

 

INFORMATION ABOUT THE NOMINEES

 

No director or executive officer of the Company is related to any other director or executive officer. None of the Company’s officers or directors holds any directorships in any other public company, except for Mr. Levin, who is a member of the board of directors of Diffusion Pharmaceuticals, Inc., and Natasha Giordano, who is a member of the board of directors (and the president and chief executive officer) of PLx Pharma Inc. A majority of our board members are independent based on the definition of independence in Listing Rule 5605(a)(2) of The NASDAQ Stock Market.

 

Set forth below is the principal occupation and employment of the nominees, the business experience of each for at least the past five years and certain other information relating to the nominees.

 

 11 
 << Previous Page | Next Page >>